[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"General Hospital of Shenyang Military Region\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":555},{"pageToken":4,"total":5,"offset":6,"count":7,"results":8},null,31,0,25,[9,42,72,98,120,142,163,182,201,221,241,257,277,296,316,341,360,378,404,425,446,466,492,512,537],{"id":10,"slug":11,"hasResults":12,"nctId":13,"briefTitle":14,"officialTitle":15,"acronym":4,"eligibilityCriteria":16,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":20,"targetDuration":4,"studyType":23,"phases":24,"briefSummary":26,"conditions":27,"keywords":4,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":30,"lastUpdatePostDateStruct":31,"startDateStruct":34,"completionDateStruct":36,"leadSponsor":38,"locationsCount":41},"100635254","phase-2-repeated-intravenous-thrombolysis-for-ischemic-stroke-with-medium-to-large-vessel-occlusion-presenting-within-45-hours-of-onset-with-prourokinase-100635254",false,"NCT07550296","Repeated Intravenous Thrombolysis for Ischemic Stroke With Medium to Large Vessel Occlusion Presenting Within 4.5 Hours of Onset With Prourokinase","Repeated Intravenous Thrombolysis for Ischemic Stroke With Medium to Large Vessel Occlusion Presenting Within 4.5 Hours of Onset With Prourokinase (RITIS-PUK): a Prospective, Randomized, Open Label, Blinded Assessment of Outcome, and Multi-center Study","Inclusion Criteria:\n\n* Age ≥ 18 year;\n* Acute ischemic stroke presumably caused by large or medium vessel occlusion within 4.5 hours of onset, having received intravenous thrombolysis of prourokinase, and with no planned thrombectomy;\n* Measurable neurological deficit before the first intravenous thrombolysis, with NIHSS ≥ 4;\n* Baseline pc-ASPECTS\u002FASPECTS ≥ 6, and for posterior circulation infarction, a Pontine-Midbrain Index ≤ 2 (assessed by CT or DWI);\n* No significant clinical improvement (reduction in NIHSS ≤ 2) or neurological deterioration after initial improvement at 1 hour after the first thrombolysis;\n* Follow-up imaging (CTA or MRA) at 1 hour after the first thrombolysis rules out intracranial hemorrhage and confirms the presence of large or medium vessel occlusion (internal carotid artery, M1-M3 segments of the middle cerebral artery, A1-A3 segments of the anterior cerebral artery, P1-P3 segments of the posterior cerebral artery, basilar artery or V4 segment of the vertebral artery, PICA, AICA, or SCA);\n* The second intravenous thrombolysis can be administered within 6 hours of onset;\n* First stroke onset or past stroke without obvious neurological deficit (mRS≤1);\n* Signed informed consent.\n\nExclusion Criteria:\n\n* Planed for endovascular treatment;\n* Significant white matter hyperintensities (Fazekas score 3);\n* Any coagulation abnormality before the first thrombolysis, including INR \\> 1.5;\n* Receipt of dual antiplatelet therapy within 24 hours prior to thrombolysis.；\n* Pregnancy；\n* Allergy to the investigational drug(s)；\n* Comorbidity with other serious diseases;\n* Participating in other clinical trials within 3 months;\n* Patients not suitable for the study considered by researcher.","ALL","18 Years","80 Years",{"count":21,"type":22},122,"ESTIMATED","INTERVENTIONAL",[25],"PHASE2","Ischemic cerebrovascular disease is a common neurological disorder with high incidence, mortality, and disability. Early reperfusion to salvage the ischemic penumbra is the cornerstone of acute ischemic stroke (AIS) treatment. Current reperfusion strategies include intravenous thrombolysis (IVT) and endovascular therapy (EVT). Although alteplase is the first-line thrombolytic agent, its recanalization rate for large vessel occlusion (LVO) is only 10-20%, and for medium vessel occlusion (MeVO), approximately 50% of patients fail to achieve recanalization, leading to poor outcomes. Prourokinase has recently been shown to be non-inferior to alteplase with a better safety profile, and studies suggest that repeated thrombolysis may improve recanalization rates in patients without early clinical improvement after standard IVT. Therefore, this study aims to evaluate the efficacy and safety of an additional intravenous infusion of prourokinase in AIS patients with confirmed medium or large vessel occlusion who show no significant clinical improvement at 1 hour after standard IVT (within 4.5 hours of symptom onset). Patients without early neurological improvement (e.g., \\\u003C2-point reduction in NIHSS) and persistent vessel occlusion on imaging will receive a second dose of prourokinase. The primary outcomes include 24-hour recanalization rate (by CTA\u002FMRA), 90-day functional outcome (modified Rankin Scale), and safety endpoints (symptomatic intracranial hemorrhage, mortality). The hypothesis is that additional prourokinase following standard IVT in non-improving patients with medium or large vessel occlusion will significantly increase recanalization rates and improve clinical outcomes without an unacceptable increase in symptomatic intracranial hemorrhage.",[28],"Acute Ischemic Stroke","RECRUITING","2026-06-29",{"date":32,"type":33},"2026-06-30","ACTUAL",{"date":35,"type":33},"2026-05-06",{"date":37,"type":22},"2027-12-30",{"name":39,"class":40},"General Hospital of Shenyang Military Region","OTHER",1,{"id":43,"slug":44,"hasResults":12,"nctId":45,"briefTitle":46,"officialTitle":47,"acronym":4,"eligibilityCriteria":48,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":49,"targetDuration":4,"studyType":23,"phases":51,"briefSummary":53,"conditions":54,"keywords":56,"overallStatus":63,"whyStopped":4,"lastUpdateSubmitDate":64,"lastUpdatePostDateStruct":65,"startDateStruct":67,"completionDateStruct":69,"leadSponsor":71,"locationsCount":41},"100642079","impact-of-propranolol-on-the-prognosis-of-patients-with-decompensated-cirrhosis-and-meld-score--9-100642079","NCT07652203","Impact of Propranolol on the Prognosis of Patients With Decompensated Cirrhosis and MELD Score > 9","Impact of Propranolol on the Prognosis of Patients With Decompensated Cirrhosis and MELD Score > 9: a Non-inferiority Randomized Controlled Trial","Inclusion Criteria:\n\n* patients' age ≥18 years;\n* patients with a definitive diagnosis of liver cirrhosis;\n* patients with a MELD score of \\>9;\n* patients with a history of decompensation or those who are experiencing their first decompensation, such as ascites, variceal bleeding, or hepatic encephalopathy (HE);\n* patients' informed consents.\n\nExclusion Criteria:\n\n* patients without a definite indication for NSBBs;\n* patients with an absolute contraindication of NSBBs (severe bronchospasm, asthma, severe psychosis, high-degree atrioventricular block, etc.);\n* patients with hypersensitivity to NSBBs;\n* patients who had been treated with NSBBs before 2 weeks of enrollment;\n* patients with occlusive portal vein thrombosis;\n* patients who had undergone liver transplantation;\n* patients who had undergone transjugular intrahepatic portosystemic shunt (TIPS);\n* patients with a definitive diagnosis of hepatocellular carcinoma;\n* patients with an estimated life time of \\\u003C12 months due to the presence of any comorbidities;\n* patients who are currently pregnant or breast-feeding.",{"count":50,"type":22},466,[52],"NA","Non selective beta blockers (NSBBs), such as propranolol and nadolol, are mainstay therapies for portal hypertension in cirrhosis, but their efficacy and safety vary depending on the stage of the disease. Emerging evidence suggests that NSBBs may worsen the prognosis of advanced cirrhosis, especially in patients with a model for end-stage liver disease (MELD) score of \\>9. The purpose of this randomized controlled trial is to evaluate the effects of the use of propranolol as recommended by the guideline on the prognosis in cirrhotic patients with a MELD score of \\>9.",[55],"Cirrhosis",[57,58,59,60,61,62],"cirrhosis","propranolol","decompensation","recompensation","survival","MELD","NOT_YET_RECRUITING","2026-06-11",{"date":66,"type":33},"2026-06-16",{"date":68,"type":22},"2026-06",{"date":70,"type":22},"2028-07",{"name":39,"class":40},{"id":73,"slug":74,"hasResults":12,"nctId":75,"briefTitle":76,"officialTitle":77,"acronym":78,"eligibilityCriteria":79,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":80,"targetDuration":4,"studyType":23,"phases":82,"briefSummary":83,"conditions":84,"keywords":86,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":90,"lastUpdatePostDateStruct":91,"startDateStruct":93,"completionDateStruct":95,"leadSponsor":97,"locationsCount":41},"100588340","direct-ischemic-conditioning-for-endovascular-recanalization-for-anterior-large-vessel-occlusion-dicer-alvo-100588340","NCT06940128","Direct Ischemic Conditioning for Endovascular Recanalization for Anterior Large Vessel Occlusion (DICER-aLVO)","Direct Ischemic Conditioning for Endovascular Recanalization for Anterior Large Vessel Occlusion (DICER-aLVO): a Prospective, Randomized, Open Label, Blinded-end Point, Phase 2, Multi-centre Study","DICER-aLVO","Inclusion Criteria:\n\n-1. Over 18 years old; 2. The time from onset to randomization is less than 24 hours; 3. Patients with acute anterior artery occlusion and receiving successful recanalization (mTICI 2b-3) after endovascular treatment and with residual stenosis ≤ 50%; 4. Cerebral circulation time after successful recanalization: affected side ≤ healthy side; 5. PH2 hemorrhage was excluded by immediate postoperative CT examination; 6. Re-onset patients with first onset or past onset without sequelae such as limb paralysis should not affect the score of this NIHSS, and mRS Score of patients with past onset should be less than 2 points; 7. Signed informed consent by patient or their legally authorized representative.\n\nExclusion Criteria:\n\n\\- 1. Spherical enlargement of the lesion site twice or more; 2. Proximal residual stenosis \\>50% for patients with tandem lesions; 3. Intracranial hemorrhagic diseases: cerebral hemorrhage, subarachnoid hemorrhage, etc.\n\n4\\. Chronic liver disease, liver and kidney insufficiency, elevated ALT or AST (greater than 2 times the upper limit of normal), elevated serum creatinine (greater than 1.5 times the upper limit of normal) or dependent on kidney dialysis; 5. Women who are pregnant, have a pregnancy plan or are breastfeeding; 6. Combined with serious other diseases, life expectancy \\\u003C 6 months; 7. Other conditions deemed inappropriate for participation in this study.",{"count":81,"type":22},120,[52],"Acute ischemic stroke (AIS) is the most common type of stroke, with high incidence rate and mortality. Endovascular therapy is currently the most effective treatment for AIS with large vessel occlusion, but only about 50% of patients achieve good outcome after endovascular therapy, while 50% of patients have poor prognosis, commonly referred to as ineffective perfusion. Therefore, how to improve ineffective perfusion is currently a hot topic.\n\nNumerous studies have shown that Remote Ischemic Therapy (RIC) has a protective effect on ischemic stroke. Our recent RICAMIS study has demonstrated that RIC can significantly improve the functional prognosis of moderate acute ischemic stroke. Furthermore, direct ischemic conditioning has also showed neuroprotective effect. For example, in a rat model, within 2 minutes after reperfusion, using three cycles of 30 s reperfusion and 10 s occlusion for direct ischemic conditioning can effectively alleviate hyperperfusion and reduce cerebral infarction volume. Meanwhile, in previous clinical exploration studies, it was found that even induction by 5-minute ischemia and 5-minute reperfusion for up to 4 cycles is safe, feasible, and well tolerated for AIS patients receiving endovascular treatment. Immediate control of bilateral carotid artery blood flow after ischemia-reperfusion can significantly reduce cerebral infarction area and brain edema, and improve neurological function recovery in rats. Subsequent molecular mechanism studies have shown that direct ischemic conditioning can reduce the production of free radicals after cerebral ischemia-reperfusion, inhibit inflammatory reactions and cell apoptosis, downregulate the expression of signaling molecules mediating brain edema, promote Akt survival pathway, and improve the integrity of the blood-brain barrier, thereby exerting neuroprotective effects. Recent studies have also confirmed the safety and feasibility of direct ischemic conditioning for stroke patients achieving successful recanalization. More importantly, a recent cohort study has shown that direct ischemic conditioning can reduce infarct growth and brain edema after reperfusion in patients with AIS who have undergone thrombectomy for occlusion of large blood vessels in the anterior circulation, and improve prognosis after 90 days.\n\nBased on the above discussion, this trial aims to evaluate the effectiveness and safety of direct ischemic conditioning for patients with AIS who have undergone thrombectomy for occlusion of large blood vessels in the anterior circulation.",[85],"Ischemic Stroke",[87,88,89],"Direct Ischemic Conditioning","stroke","Endovascular Recanalization","2026-04-22",{"date":92,"type":33},"2026-04-27",{"date":94,"type":33},"2025-03-31",{"date":96,"type":22},"2027-03-31",{"name":39,"class":40},{"id":99,"slug":100,"hasResults":12,"nctId":101,"briefTitle":102,"officialTitle":103,"acronym":104,"eligibilityCriteria":105,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":106,"targetDuration":4,"studyType":23,"phases":108,"briefSummary":109,"conditions":110,"keywords":111,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":90,"lastUpdatePostDateStruct":114,"startDateStruct":115,"completionDateStruct":117,"leadSponsor":119,"locationsCount":41},"100587680","remote-ischemic-conditioning-for-acute-moderate-posterior-ischemic-stroke-100587680","NCT06931535","Remote Ischemic Conditioning for Acute Moderate Posterior Ischemic Stroke","Remote Ischemic Conditioning for Acute Moderate Posterior Ischemic Stroke (RICAMIS2): a Prospective, Random, Open Label, Blinded End Point, Multi-center Study","RICAMIS2","Inclusion Criteria:\n\n* Age ≥18 years;\n* Time from onset to treatment: ≤48 hours;\n* Posterior circulation ischemic stroke confirmed by CT or MRI, including patients who have received intravenous thrombolysis or endovascular therapy;\n* NIHSS score at randomization: 6-16, with an item 1a (level of consciousness) score of 0-1;\n* First-ever stroke or prior stroke without significant residual disability (modified Rankin Scale score ≤1);\n* Signed informed consent.\n\nExclusion Criteria:\n\n* intracerebral hemorrhage or subarachnoid hemorrhage；\n* Uncontrolled severe hypertension (systolic blood pressure \\>180 mmHg or diastolic blood pressure \\>110 mmHg despite antihypertensive therapy)；\n* Subclavian artery stenosis ≥ 50% or subclavian steal syndrome;\n* Intracranial tumor, arteriovenous malformation or aneurysm;\n* Severe abnormalities in coagulation;\n* Any contraindication for remote ischemic adaptation: the upper limb has serious soft tissue injury, fracture or vascular injury, distal upper limb perivascular lesions, etc.;\n* Participating in other clinical trials within 3 months;\n* Comorbidity with any serious diseases and life expectancy is less than half a year;\n* Patients not suitable for this clinical studies considered by researcher;",{"count":107,"type":22},960,[52],"A substantial body of basic and clinical research has demonstrated the protective effects of remote ischemic conditioning (RIC) in ischemic stroke. While these clinical studies support the safety of RIC, the neuroprotective benefits of RIC in acute ischemic stroke (AIS) patients lack robust evidence due to small sample sizes, heterogeneous RIC protocols, and variability in the severity of neurological deficits among study populations. Our recent multicenter randomized clinical trial, the RICAMIS study, investigated the efficacy of RIC in patients with acute moderate ischemic stroke. The results showed that RIC administered within 48 hours of onset significantly improved 90-day neurological outcomes in patients with moderate stroke severity. It is well established that anterior circulation stroke (ACS) and posterior circulation stroke (PCS) differ in multiple aspects, including anatomical structure, collateral circulation, blood supply, clinical manifestations, prognosis, ischemic tolerance time, and treatment response. For instance, compared to the anterior circulation, the posterior circulation has poorer collateral circulation, a higher proportion of stroke etiologies attributed to atherosclerosis, and longer ischemic tolerance time. Consequently, intravenous thrombolysis and endovascular therapy may offer a more extended therapeutic time window for PCS patients. A prespecified subgroup analysis of the RICAMIS study revealed that patients with PCS derived greater benefit from RIC than those with ACS. However, this finding requires further validation through prospective studies, as prior research has never specifically examined the efficacy of RIC in PCS patients.\n\nBased on the above discussion, this study aims to investigate the efficacy and safety of RIC in patients with acute moderate PCS.",[85],[112,113],"posterior circulation stroke","remote ischemic conditioning",{"date":92,"type":33},{"date":116,"type":33},"2025-04-13",{"date":118,"type":22},"2026-12-30",{"name":39,"class":40},{"id":121,"slug":122,"hasResults":12,"nctId":123,"briefTitle":124,"officialTitle":125,"acronym":126,"eligibilityCriteria":127,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":128,"targetDuration":4,"studyType":23,"phases":130,"briefSummary":131,"conditions":132,"keywords":133,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":90,"lastUpdatePostDateStruct":137,"startDateStruct":138,"completionDateStruct":140,"leadSponsor":141,"locationsCount":41},"100574759","balloon-angioplasty-for-minor-unstable-stroke-with-intracranial-atherosclerosis-stenosis-bamus-icas-100574759","NCT06763458","Balloon Angioplasty for Minor Unstable Stroke With IntraCranial Atherosclerosis Stenosis (BAMUS-ICAS)","Balloon Angioplasty for Minor Unstable Stroke With IntraCranial Atherosclerosis Stenosis (BAMUS-ICAS): a Prospective, Randomized, Multi-center Study","BAMUS-ICAS","Inclusion Criteria:\n\n1. Over 18 years of age;\n2. Minor ischemic stroke within 1 week of onset (NIHSS≤5);\n3. Have received the best drug treatment (dual antibody, anti-plate combined with anticoagulation), but symptoms still have measurable fluctuations or progression (NIHSS increased by at least 1 point);\n4. Symptoms fluctuate to the time of receiving balloon dilation within 24 hours;\n5. The etiology was considered to be severe stenosis of the responsible vessels due to intracranial arteriosclerosis (70-99% stenosis), or perforator artery disease with severe stenosis of the carrier artery (confirmed by MRA, CTA or DSA);\n6. Patients with first onset or past onset without sequelae such as limb paralysis should not affect the score of this NIHSS, and mRS Score of patients with past onset should be less than 2 points;\n7. Patients or family members sign informed consent.\n\nExclusion Criteria:\n\n1. Patients who have developed large intracranial vessel occlusion;\n2. Intracranial hemorrhagic diseases in the past 3 months: cerebral hemorrhage, subarachnoid hemorrhage, etc.;\n3. Non-atherosclerotic disease-related stenosis: arterial dissection, moya-moya disease, arterioinflammatory disease, etc.\n4. Clotting disorders or systemic bleeding tendency or platelets less than 100,000;\n5. Complicated with serious infection or liver, kidney and other serious diseases;\n6. Patients with severe inability to control hypertension (systolic blood pressure \\>200mmHg or diastolic blood pressure \\>110mmHg);\n7. Women who are pregnant, have a pregnancy plan or are breastfeeding;\n8. Complicated with other serious diseases, life expectancy \\\u003C 6 months; Other conditions deemed inappropriate for participation in this study.",{"count":129,"type":22},100,[52],"Intracranial atherosclerotic stenosis (ICAS) is a common cause of stroke, especially in East and South Asia, and is significantly associated with stroke recurrence and early neurological deterioration (END) despite aggressive medical management. Minor stroke (National Institutes of Health Stroke, NIHSS score ≤ 5) patients with ICAS often has higher risk of END. The early realization of blood flow patency is closely related to the improvement of patient outcomes. Submaximal balloon angioplasty (SBA) as a safer and simpler intervention which can improve cerebral blood flow. Thus, SBA may be an effective strategy for preventing END in acute ischemic stroke patients with ICAS.",[85],[88,134,135,136],"Submaximal balloon angioplasty","early neurological deterioration","Intracranial atherosclerotic stenosis",{"date":92,"type":33},{"date":139,"type":33},"2025-02-19",{"date":37,"type":22},{"name":39,"class":40},{"id":143,"slug":144,"hasResults":12,"nctId":145,"briefTitle":146,"officialTitle":147,"acronym":148,"eligibilityCriteria":149,"healthyVolunteers":12,"sex":17,"minAge":150,"maxAge":4,"enrollmentInfo":151,"targetDuration":4,"studyType":23,"phases":153,"briefSummary":154,"conditions":155,"keywords":4,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":90,"lastUpdatePostDateStruct":157,"startDateStruct":158,"completionDateStruct":160,"leadSponsor":162,"locationsCount":41},"100529220","effect-of-remote-ischemic-preconditioning-on-collaterals-of-atherosclerosis-stroke-100529220","NCT06170944","Effect of Remote Ischemic Preconditioning on Collaterals of Atherosclerosis Stroke","Effect of Remote Ischemic Preconditioning on Collaterals of Atherosclerosis Stroke (RICAS): a Prospective, Randomized, Blind Endpoint, Multicenter Study","RICAS","Inclusion Criteria:\n\n* 1\\. Age over 40 years old;\n* 2\\. Diagnosed with ischemic stroke (including TIA and cerebral infarction), with onset time of more than 1 month;\n* 3\\. Culprit arteries are the large arteries of the anterior circulation with atherosclerotic stenosis (≥50%) or occlusion;\n* 4\\. ASITN\u002FSIR collateral circulation of 0-3 based on DSA evaluation;\n* 5\\. First onset or prior onset with no significant sequelae (mRS ≤ 2);\n* 6\\. Those who are not expected to undergo angioplasty within 12 months (judged by the doctor or decided by patients and\u002For their representatives);\n* 7\\. The availability of informed consent.\n\nExclusion Criteria:\n\n* 1\\) Patients with severe infection or serious diseases such as liver, kidney, hematopoietic system, endocrine system, etc.;\n* 2\\) Patients with a history of stroke and severe sequelae (mRS≥3);\n* 3\\) arterial stenosis due to aortic dissection, moyamoya disease; Any known vasculitic disease; herpes zoster, varicella-zoster or other viral infections with vascular lesions; neurosyphilis; other intracranial infections; any intracranial artery stenosis associated with hypercytosis of cerebrospinal fluid; radiation-induced vascular lesions; myofiber dysplasia; sickle cell disease; neurofibromas; benign vascular lesions of the central nervous system; postpartum vascular disease; stenosis of the intracranial arteries due to vasospasm or thrombosm;\n* 4\\) Uncontrolled severe hypertension (systolic pressure≥180mmHg or diastolic pressure≥110 mmHg after drug treatment) ;\n* 5\\) Subclavian artery stenosis ≥50% or subclavian artery steal syndrome;\n* 6\\) Patients with intracranial hemorrhage (parenchymal hemorrhage, subarachnoid hemorrhage, subdural\u002Fepidural hemorrhage) within 90 days before enrollment;\n* 7\\) Intracranial tumor, arteriovenous malformation, or aneurysm;\n* 8\\) Patients with severe hematologic diseases or severe coagulation abnormalities;\n* 9\\) Retinal hemorrhage or visceral hemorrhage within 30 days;\n* 10\\) Those who are expected to undergo major surgery (including femoral artery, cardiac, aortic or carotid artery surgery) within 30 days before enrollment or within 12 months after enrollment;\n* 11\\) Those who have received stent implantation, angioplasty or other related medical devices for the target diseased blood vessels, or those who are expected to undergo the above treatments within 12 months after enrollment;\n* 12\\) Any contraindication for remote ischemic adaptation: the upper limb has serious soft tissue injury, fracture or vascular injury, distal upper limb perivascular lesions, etc.\n* 13\\) Damage and lesions in the cerebral veins;\n* 14\\) Pregnant or lactating women;\n* 15\\) Those who are participating in other clinical trials within 3 months;\n* 16\\) Life expectancy is less than 1 year\n* 17\\) Patients not suitable for this clinical studies considered by researcher","40 Years",{"count":152,"type":22},300,[52],"The goal of this clinical trial is to explore the influence of chronic RIC on collateral status evaluated by DSA in ischemic stroke patients with LAA etiology.",[156],"Stroke, Ischemic",{"date":92,"type":33},{"date":159,"type":33},"2024-06-01",{"date":161,"type":22},"2027-11-30",{"name":39,"class":40},{"id":164,"slug":165,"hasResults":12,"nctId":166,"briefTitle":167,"officialTitle":168,"acronym":4,"eligibilityCriteria":169,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":170,"targetDuration":4,"studyType":23,"phases":172,"briefSummary":173,"conditions":174,"keywords":4,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":90,"lastUpdatePostDateStruct":176,"startDateStruct":177,"completionDateStruct":179,"leadSponsor":181,"locationsCount":41},"100516907","trendelenburg-position-for-acute-anterior-circulation-ischemic-stroke-with-large-artery-atherosclerosis-etiology-hopes-3-100516907","NCT06010641","Trendelenburg Position for Acute Anterior Circulation Ischemic Stroke With Large Artery Atherosclerosis Etiology (HOPES 3)","Trendelenburg Position for Acute Anterior Circulation Ischemic Stroke With Large Artery Atherosclerosis Etiology (HOPES 3): a Prospective, Randomized, Open-label, Blinded-endpoint, Multi-center Trial","Inclusion Criteria:\n\n* Age ≥ 18 years old\n* Acute ischemic stroke confirmed by NCCT or MRI;\n* Moderate neurologic deficit (6≤ NIHSS ≤ 16) within 24 hours of onset, or progressing from mild (NIHSS ≤ 5) to moderate neurologic deficit (6≤ NIHSS ≤ 16) within 24 hours, requiring ≥ 4 point increase in NIHSS score although the onset time is beyond 24 hours;\n* Probable large artery atherosclerosis etiology based on the Trial of Org 10172 in Acute Stroke Treatment (TOAST) criteria (responsible artery stenosis ≥ 50% or occlusion);\n* Anterior circulation stroke (internal carotid artery, M1 or M2 of middle cerebral artery);\n* First stroke onset or past stroke without obvious neurological deficit (mRS≤2);\n* Signed informed consent.\n\nExclusion Criteria:\n\n* Pre-stroke disability (mRS≥3);\n* Patients with disturbance of consciousness;\n* Patients who plan to undergo or have completed thrombolysis or mechanical thrombectomy;\n* Hemorrhagic stroke or combined ischemic and hemorrhagic stroke;\n* Serious comorbidity, such as liver or kidney insufficiency, malignant tumor, etc;\n* Other stroke etiologies, such as cardiogenic embolism, arteritis, arterial dissection, moyamoya disease, etc;\n* Previous history of intracerebral hemorrhage within 1 year;\n* Any contraindication to head-down position (e.g. active vomiting, pneumonia, uncontrolled heart failure);\n* Planned carotid or intracranial revascularization within 3 months;\n* Severe uncontrolled hypertension (systolic blood pressure over 180mmHg or diastolic blood pressure over 100 mmHg);\n* Cardiac insufficiency (NYHA Class ≥II);\n* Pregnant or lactating women;\n* Comorbidity with other serious diseases;\n* Participating in other clinical trials within 3 months;\n* Patients not suitable for the study considered by researcher.",{"count":171,"type":22},600,[52],"The effect of head position as a nonpharmacological therapy on acute ischemic stroke (AIS) remains inconclusive. Recent HOPES2 (Head dOwn-Position for acutE moderate ischemic Stroke with large artery atherosclerosis) suggest the safety, feasibility, and potential benefit of the head-down position (HDP) in acute ischemic stroke. The current study aims to investigate the efficacy and safety of HDP in acute moderate ischemic stroke patients with large artery atherosclerosis.",[175],"Stroke, Acute Ischemic",{"date":92,"type":33},{"date":178,"type":33},"2024-01-10",{"date":180,"type":22},"2027-10-30",{"name":39,"class":40},{"id":183,"slug":184,"hasResults":12,"nctId":185,"briefTitle":186,"officialTitle":187,"acronym":188,"eligibilityCriteria":189,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":190,"targetDuration":4,"studyType":23,"phases":191,"briefSummary":193,"conditions":194,"keywords":4,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":90,"lastUpdatePostDateStruct":196,"startDateStruct":197,"completionDateStruct":199,"leadSponsor":200,"locationsCount":41},"100343585","phase-4-the-effect-of-intensive-statin-in-ischemic-stroke-with-intracranial-atherosclerotic-plaques-100343585","NCT03753555","The Effect of InTensive Statin in Ischemic Stroke With inTracranial Atherosclerotic Plaques","The Effect of InTensive Statin in Ischemic Stroke With inTracranial Atherosclerotic Plaques: a Prospective, Random, Single-center Study Based on High Resolution Magnetic Resonance Imaging","INSIST-HRMRI","Inclusion Criteria:\n\n1. Patient age between 18-80 years\n2. Time of onset: within 1 week\n3. NIHSS score ≤12\n4. Acute ischemic stroke confirmed by head CT or MRI\n5. Premorbid mRS ≤1\n6. The degree of stenosis of carotid artery, vertebral artery and intracranial portion of internal carotid artery on the lesion side \\\u003C50%\n7. The culprit plaque or possible culprit plaque with plaque burden of 40% or more found by HRMRI in the proximal part of the middle cerebral artery M1 segment or basilar artery of ipsilateral lesion\n8. Signed informed consent\n\nExclusion Criteria:\n\n1. Intracranial hemorrhage found by head CT\n2. Stroke attributable to cardioembolic origin (atrial fibrillation, valvular heart disease, aortic arch atherosclerosis)\n3. Severe hepatic or renal dysfunction\n4. Pregnant females\n5. Abnormal elevation of creatine phosphokinase\n6. Expected stent angioplasty\n7. Blood sugar is out of control\n8. Receiving statins within 1 month before onset\n9. Obstinate hypertension with more than 140\u002F90 mmHg after medication\n10. Not willing and able to comply with scheduled visits, lifestyle guidelines, treatment plan, laboratory tests, and other study procedures\n11. Unsuitable for this clinical studies assessed by researcher",{"count":129,"type":22},[192],"PHASE4","Intracranial atherosclerotic disease is the most common cause of ischemic stroke that is directly attributed to the progression or rupture of intracranial high-risk plaque in Asia. Many studies mainly from Euro-American population with a focus on extracranial carotid plaque have fully demonstrated the advantages of intensive statin therapy on stabilizing or reversing plaque burden, reversing plaque composition presenting that lipid-rich necrotic core (LRNC) is gradually replaced by fibrous tissue, and even reversing pattern of arterial remodeling to reduce the occurrence of cerebrovascular events. Yet, direct evidence of the effect of intensive statin therapy on intracranial atherosclerotic plaques is lacking and the effect of statin intensity and duration on intracranial plaque burden and composition is still unclear. High resolution magnetic resonance imaging (HRMRI) is a new and non-invasive technique that enable to assess the morphologic characteristics of vascular wall and plaque composition of intracranial artery. Based on above discussion, the investigators conduct this study to further determine the effect of intensive statin in ischemic stroke with intracranial atherosclerotic plaques.",[156,195],"Atherosclerosis, Cerebral",{"date":92,"type":33},{"date":198,"type":33},"2018-12-01",{"date":161,"type":22},{"name":39,"class":40},{"id":202,"slug":203,"hasResults":12,"nctId":204,"briefTitle":205,"officialTitle":206,"acronym":4,"eligibilityCriteria":207,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":208,"targetDuration":4,"studyType":210,"phases":4,"briefSummary":211,"conditions":212,"keywords":213,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":90,"lastUpdatePostDateStruct":216,"startDateStruct":217,"completionDateStruct":219,"leadSponsor":220,"locationsCount":41},"100329633","the-impact-of-anti-thrombosis-on-cerebral-microbleeds-and-intracranial-hemorrhage-in-ischemic-stroke-patients-100329633","NCT03571763","The Impact of Anti-thrombosis on Cerebral Microbleeds and Intracranial Hemorrhage in Ischemic Stroke Patients","The Impact of Anti-thrombosis on Cerebral Microbleeds and Intracranial Hemorrhage in Ischemic Stroke Patients: Prospective, Multi-center, Cohort Study","Inclusion Criteria:\n\n1. Patient age ≥18 years;\n2. Acute ischemic stroke patient confirmed by imaging;\n3. Time of onset: within 3 months;\n4. Baseline SWI sequence is completed before starting the secondary prevention of ischemic stroke;\n5. Baseline SWI sequence must have at least one CMB ;\n6. NIHSS≤10\n\nExclusion Criteria:\n\n1. MRI contraindication;\n2. Hemorrhagic transformation after acute Ischemic stroke;\n3. Contraindication for antiplatelet or anticoagulation therapy;\n4. Severe head trauma or intracranial hemorrhage occurred in the past six months;\n5. obvious coagulopathy;\n6. Other intracranial lesions associated with (such as tumor, cerebral vascular malformation);\n7. other unqualified patients judged by the investigator",{"count":209,"type":22},1875,"OBSERVATIONAL","The purpose of this prospective cohort study is to investigate whether antithrombotic therapy in the secondary prevention of ischemic stroke increases the risk of the emerging CMBs and whether the change is associated with an increased risk of intracranial hemorrhage, providing an imaging evidence for individualized antithrombotic therapy in such patients.",[85],[214,215],"Cerebral Hemorrhage","anti-thrombosis",{"date":92,"type":33},{"date":218,"type":33},"2018-08-01",{"date":118,"type":22},{"name":39,"class":40},{"id":222,"slug":223,"hasResults":12,"nctId":224,"briefTitle":225,"officialTitle":226,"acronym":227,"eligibilityCriteria":228,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":229,"targetDuration":4,"studyType":23,"phases":231,"briefSummary":232,"conditions":233,"keywords":4,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":234,"lastUpdatePostDateStruct":235,"startDateStruct":237,"completionDateStruct":239,"leadSponsor":240,"locationsCount":41},"100621849","phase-2-repeated-intravenous-thrombolysis-for-ischemic-stroke-with-medium-to-large-vessel-occlusion-presenting-within-45-hours-of-onset-with-tenecteplase-ritis-tnk2-100621849","NCT07375966","Repeated Intravenous Thrombolysis for Ischemic Stroke With Medium to Large Vessel Occlusion Presenting Within 4.5 Hours of Onset With Tenecteplase (RITIS-TNK2)","Repeated Intravenous Thrombolysis for Ischemic Stroke With Medium to Large Vessel Occlusion Presenting Within 4.5 Hours of Onset With Tenecteplase (RITIS-TNK2): a Prospective, Randomized, Open Label, Blinded Assessment of Outcome, and Multi-center Study","RITIS-TNK2","Inclusion Criteria:\n\n* Age ≥ 18 year;\n* Acute ischemic stroke presumably caused by large or medium vessel occlusion within 4.5 hours of onset, having received standard-dose intravenous thrombolysis, and with no planned thrombectomy;\n* Measurable neurological deficit before the first intravenous thrombolysis, with NIHSS ≥ 4;\n* Baseline pc-ASPECTS\u002FASPECTS ≥ 6, and for posterior circulation infarction, a Pontine-Midbrain Index ≤ 2 (assessed by CT or DWI);\n* No significant clinical improvement (reduction in NIHSS ≤ 2) or neurological deterioration after initial improvement at 1 hour after the first thrombolysis;\n* Follow-up imaging (CTA or MRA) at 1 hour after the first thrombolysis rules out intracranial hemorrhage and confirms the presence of large or medium vessel occlusion (internal carotid artery, M1-M3 segments of the middle cerebral artery, A1-A3 segments of the anterior cerebral artery, P1-P3 segments of the posterior cerebral artery, basilar artery or V4 segment of the vertebral artery, PICA, AICA, or SCA);\n* The second intravenous thrombolysis can be administered within 6 hours of onset;\n* First stroke onset or past stroke without obvious neurological deficit (mRS≤1);\n* Signed informed consent.\n\nExclusion Criteria:\n\n* Planed for endovascular treatment;\n* Significant white matter hyperintensities (Fazekas score 3);\n* Any coagulation abnormality before the first thrombolysis, including INR \\> 1.5;\n* Receipt of dual antiplatelet therapy within 24 hours prior to thrombolysis.；\n* Pregnancy；\n* Allergy to the investigational drug(s)；\n* Comorbidity with other serious diseases;\n* Participating in other clinical trials within 3 months;\n* Patients not suitable for the study considered by researcher.",{"count":230,"type":22},198,[25],"While intravenous thrombolysis (IVT) within 4.5 hours is the standard medical reperfusion therapy, its efficacy is limited, particularly for large or medium vessel occlusions (LVO\u002FMeVO), with low recanalization rates for IVT with rt-PA. The newer thrombolytic agent, tenecteplase (TNK), offers practical advantages-including single bolus administration, a longer half-life, and potentially higher fibrin specificity-and has been shown to be non-inferior to rt-PA.\n\nDespite advances, a significant proportion of patients with LVO\u002FMeVO do not achieve early clinical improvement after standard IVT, likely due to persistent occlusion from a high thrombus burden. Endovascular therapy, while highly effective for LVO, has limited accessibility. Therefore, there is an urgent need for more effective and widely accessible pharmacological strategies.\n\nThis study proposes a rescue strategy based on the hypothesis that a second dose of IVT may improve outcomes in patients with imaging-confirmed LVO or MeVO who show no significant neurological improvement one hour after standard TNK thrombolysis (administered within 4.5 hours of stroke onset). The primary aim of this study is to formally evaluate the efficacy and safety of a repeated dose of intravenous tenecteplase in this specific patient population.",[85],"2026-03-31",{"date":236,"type":33},"2026-04-01",{"date":238,"type":33},"2026-03-25",{"date":37,"type":22},{"name":39,"class":40},{"id":242,"slug":243,"hasResults":12,"nctId":244,"briefTitle":245,"officialTitle":246,"acronym":247,"eligibilityCriteria":248,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":249,"targetDuration":4,"studyType":23,"phases":250,"briefSummary":251,"conditions":252,"keywords":4,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":234,"lastUpdatePostDateStruct":253,"startDateStruct":254,"completionDateStruct":255,"leadSponsor":256,"locationsCount":41},"100621848","phase-2-repeated-intravenous-thrombolysis-for-ischemic-stroke-within-30-hours-of-onset-with-tenecteplase-ritis-tnk-100621848","NCT07375953","Repeated Intravenous Thrombolysis for Ischemic Stroke Within 3.0 Hours of Onset With Tenecteplase (RITIS-TNK)","Repeated Intravenous Thrombolysis for Ischemic Stroke Within 3.0 Hours of Onset With Tenecteplase (RITIS-TNK): a Prospective, Randomized, Open Label, Blinded Assessment of Outcome, and Multi-center Study","RITIS-TNK","Inclusion Criteria:\n\n* Age ≥ 18 year;\n* Acute ischemic stroke within 3 hours of onset, having received standard intravenous thrombolysis;\n* Measurable neurological deficit before the first intravenous thrombolysis, with NIHSS ≥ 4;\n* No significant clinical improvement (reduction in NIHSS ≤ 2) or neurological deterioration after initial improvement at 1 hour after the first thrombolysis, with intracranial hemorrhage ruled out by neuroimaging;\n* The second intravenous thrombolysis can be administered within 4.5 hours of onset;\n* First stroke onset or past stroke without obvious neurological deficit (mRS≤1);\n* Signed informed consent.\n\nExclusion Criteria:\n\n* Planed for endovascular treatment;\n* Significant cerebral white matter hyperintensities (Fazekas score 3)；\n* Any coagulation abnormality before the first thrombolysis, including INR \\> 1.5；\n* Pregnancy；\n* Allergy to the investigational drug(s)；\n* Receipt of dual antiplatelet therapy within 24 hours prior to thrombolysis;\n* Comorbidity with other serious diseases;\n* Participating in other clinical trials within 3 months;\n* Patients not suitable for the study considered by researcher.",{"count":81,"type":22},[25],"Despite being the standard pharmacological reperfusion therapy for acute ischemic stroke, intravenous thrombolysis is limited by suboptimal recanalization rates. Tenecteplase (TNK), a newer thrombolytic agent, offers practical advantages over alteplase, including single bolus administration. However, a significant proportion of patients fail to achieve early clinical improvement after standard thrombolysis, likely due to persistent vessel occlusion.\n\nThis study proposes to investigate a rescue strategy for patients who do not show significant neurological improvement within one hour after receiving standard intravenous tenecteplase within 3 hours of stroke onset. The primary objective is to evaluate the safety and feasibility of administering a second dose of tenecteplase in this scenario. The study will also explore the potential efficacy of this approach in improving recanalization and functional outcomes.",[85],{"date":236,"type":33},{"date":238,"type":33},{"date":37,"type":22},{"name":39,"class":40},{"id":258,"slug":259,"hasResults":12,"nctId":260,"briefTitle":261,"officialTitle":262,"acronym":263,"eligibilityCriteria":264,"healthyVolunteers":12,"sex":17,"minAge":150,"maxAge":4,"enrollmentInfo":265,"targetDuration":4,"studyType":23,"phases":266,"briefSummary":267,"conditions":268,"keywords":4,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":270,"lastUpdatePostDateStruct":271,"startDateStruct":273,"completionDateStruct":275,"leadSponsor":276,"locationsCount":41},"100624639","remote-ischemic-conditioning-plus-stenting-for-symptomatic-carotid-artery-stenosis-100624639","NCT07412249","Remote Ischemic Conditioning Plus Stenting for Symptomatic Carotid Artery Stenosis","Remote Ischemic Conditioning Plus Stenting for Symptomatic Carotid Artery Stenosis (RICSICAS): A Prospective, Randomized Controlled, Blind Endpoint, Single-Center Study","RICSICAS","Inclusion Criteria:\n\n* Age ≥ 40 years old;\n* Patients with symptomatic moderate to severe stenosis of the internal carotid artery;\n* History of ipsilateral cerebral ischemic symptoms within the past 180 days;\n* Planned for carotid artery stent;\n* Essen Score ≥ 3;\n* Modified Rankin Scale score of 0 or 1;\n* Signed informed consent.\n\nExclusion Criteria:\n\n* Uncontrolled severe hypertension (systolic blood pressure \\> 180 mmHg or diastolic blood pressure \\> 110 mmHg despite medication)\n* Subclavian artery stenosis ≥ 50% or presence of subclavian steal syndrome\n* Severe hematological disorders or significant coagulation abnormalities\n* Contraindications to remote ischemic conditioning, such as severe soft tissue injury, fracture, or vascular injury in the upper limbs, or peripheral vascular disease in the distal upper limbs\n* Severe comorbid conditions with a life expectancy of less than 1 year\n* Participation in another clinical trial within the past 3 months or ongoing participation\n* Any other circumstances deemed by the investigator as unsuitable for participation in this clinical study.",{"count":152,"type":22},[52],"Remote ischemic conditioning (RIC) has emerged as a promising non-invasive strategy to protect the brain, with evidence suggesting its benefit in patients with carotid artery stenting (CAS). However, the long-term benefit and safety of chronic RIC in this population remain unknown. This trial aims to evaluate whether chronic RIC reduces the incidence of major vascular events and improves clinical outcomes in high-risk patients with carotid artery stenosis who received CAS.",[269],"Carotid Stenosis","2026-03-30",{"date":272,"type":33},"2026-04-03",{"date":274,"type":33},"2026-03-04",{"date":161,"type":22},{"name":39,"class":40},{"id":278,"slug":279,"hasResults":12,"nctId":280,"briefTitle":281,"officialTitle":282,"acronym":4,"eligibilityCriteria":283,"healthyVolunteers":12,"sex":17,"minAge":150,"maxAge":4,"enrollmentInfo":284,"targetDuration":4,"studyType":23,"phases":286,"briefSummary":287,"conditions":288,"keywords":4,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":290,"lastUpdatePostDateStruct":291,"startDateStruct":292,"completionDateStruct":293,"leadSponsor":295,"locationsCount":41},"100628508","transcranial-doppler-for-internal-carotid-artery-stenting-tcd-icas-100628508","NCT07462546","Transcranial Doppler for Internal Carotid Artery Stenting (TCD-ICAS)","Transcranial Doppler for Internal Carotid Artery Stenting (TCD-ICAS): A Prospective, Randomized Controlled, Blind Endpoint, Single-Center Study","Inclusion Criteria:\n\n* Age ≥ 40 years old;\n* Patients with severe stenosis of the internal carotid artery;\n* Planned for carotid artery stent;\n* Modified Rankin Scale score ≤ 2;\n* The subject has adequate temporal bone windows to undergo TCD, and the blood flow signal of the middle cerebral artery is detectable.;\n* Signed informed consent by patient or their legally authorized representative.\n\nExclusion Criteria:\n\n* Comorbid conditions with severe infections or severe diseases of the liver, kidney, hematopoietic system, endocrine system, etc.;\n* Occurrence of intracranial hemorrhage (cerebral parenchymal hemorrhage, subarachnoid hemorrhage, subdural\u002Fepidural hemorrhage) within 90 days prior to enrollment;\n* Severe hematological disorders or significant coagulation abnormalities;\n* Pregnant or breastfeeding women;\n* Participation in another clinical trial within the past 3 months or ongoing participation;\n* Any other circumstances deemed by the investigator as unsuitable for participation in this clinical study.",{"count":285,"type":22},232,[52],"Carotid artery stenting (CAS) prevents stroke but carries risks of perioperative cerebral embolism. Transcranial Doppler (TCD) ultrasound can detect microemboli during CAS and may offer therapeutic benefits through ultrasound-enhanced thrombolysis. Trials like SONOBUSTER and SONOBIRDIE suggest TCD reduces new brain infarctions during carotid procedures. The TCD-ICAS trial will investigate whether TCD application during and after CAS reduces perioperative cerebral emboli and improves outcomes.",[289],"Artery Stenosis","2026-03-24",{"date":238,"type":33},{"date":290,"type":33},{"date":294,"type":22},"2026-11-30",{"name":39,"class":40},{"id":297,"slug":298,"hasResults":12,"nctId":299,"briefTitle":300,"officialTitle":301,"acronym":4,"eligibilityCriteria":302,"healthyVolunteers":12,"sex":17,"minAge":303,"maxAge":19,"enrollmentInfo":304,"targetDuration":4,"studyType":23,"phases":306,"briefSummary":307,"conditions":308,"keywords":4,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":290,"lastUpdatePostDateStruct":310,"startDateStruct":311,"completionDateStruct":313,"leadSponsor":315,"locationsCount":41},"100615613","deep-cervical-lymphatic-venous-anastomosis-for-alzheimers-disease-100615613","NCT07294885","Deep Cervical LymphatIc-Venous Anastomosis for Alzheimer's Disease","Deep Cervical LymphatIc-Venous Anastomosis for Alzheimer's Disease (CLIVA-AD): a Prospective, Single-center, Randomized, Double Blinded Trial","Inclusion Criteria:\n\n* Age 50-80 years (inclusive), regardless of gender.\n* Meeting the diagnostic criteria for Mild Cognitive Impairment or mild to moderate dementia due to Alzheimer's disease (according to the 2024 AA clinical diagnostic criteria for AD-related dementia).\n* Disease duration of 6 months or longer, with no clinical improvement after 3 months or more of conservative treatment.\n* MMSE score: 12-26.\n* Biomarker confirmation of AD: positive Aβ-PET and tau-PET, or positive cerebrospinal fluid biomarkers.\n* Having a reliable caregiver (providing companionship for ≥3 hours per day).\n* Signed written informed consent from the patient or legally authorized representative.\n\nExclusion Criteria:\n\n* Contraindications to MRI, ICG angiography, or PET.\n* Contraindications to surgery or anesthesia, such as coagulation disorders (platelet count \\\u003C100×10⁹\u002FL, INR \\>1.7).\n* Comorbid major organ dysfunction, such as reduced left ventricular ejection fraction, severe hepatic or renal insufficiency (AST or ALT \\>3 times the upper limit of normal; eGFR \\\u003C30 mL\u002Fmin\u002F1.73m²).\n* Intracranial structural lesions indicated by MRI, including brain tumors, cerebral infarction, intracranial hemorrhage, aneurysms, arteriovenous malformations, hydrocephalus, etc.\n* MRI findings suggestive of significant cerebral small vessel disease features: more than one lacunar infarction in the deep white matter and periventricular regions and\u002For white matter hyperintensity (WMH) with a Fazekas grade \\>2, or the presence of ≥4 cerebral microbleeds.\n* Other causes of dementia, such as hypothyroidism or vitamin B12 deficiency.\n* Drug\u002Falcohol addiction.\n* Severe psychiatric illness or suicide risk.\n* Comorbid medical conditions with a life expectancy of less than 1 year.\n* Participation in another interventional trial within the past 3 months.\n* Poor compliance or judged by the investigator as unsuitable for participation.\n* Patients receiving therapy with Lecanemab or Donanemab.\n* Other conditions that the researcher deems unsuitable for participation in this study.","50 Years",{"count":305,"type":22},50,[52],"Lymphaticovenous anastomosis (LVA) is a microsurgical technique that involves anastomosing fine lymphatic vessels with adjacent veins to reestablish lymphatic drainage pathways. It is used in the treatment of lymphedema-related conditions and is characterized by minimal invasiveness and rapid recovery. Based on findings from animal studies, some physicians in China have attempted deep cervical lymphatic-venous anastomosis to improve intracranial lymphatic drainage in patients with Alzheimer's disease (AD). Most studies, including those from our center, have observed early postoperative improvements in various domains such as mood, memory, executive function, and communication abilities in the majority of patients. However, these symptomatic improvements are not sustained. The reasons for the early improvements remain unclear. Are they due to enhanced lymphatic drainage resulting from the surgery itself, or are they attributable to other factors such as anesthetic effects, vascular release, or modulation of sympathetic nerves? Therefore, it is necessary to conduct a randomized controlled trial with a sham surgery group to clarify the causes of early clinical symptom improvements. Based on this, this project aims to carry out a prospective, single-center, randomized double-blind controlled study to evaluate whether the early symptomatic improvements following deep cervical LVA in AD patients are attributable to the surgical intervention itself or to other aspects of the procedure.",[309],"Alzheimer Disease",{"date":238,"type":33},{"date":312,"type":33},"2026-03-20",{"date":314,"type":22},"2027-08-30",{"name":39,"class":40},{"id":317,"slug":318,"hasResults":12,"nctId":319,"briefTitle":320,"officialTitle":321,"acronym":4,"eligibilityCriteria":322,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":323,"enrollmentInfo":324,"targetDuration":4,"studyType":23,"phases":326,"briefSummary":327,"conditions":328,"keywords":330,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":333,"lastUpdatePostDateStruct":334,"startDateStruct":336,"completionDateStruct":338,"leadSponsor":340,"locationsCount":41},"100622807","adding-evolocumab-to-conventional-lipid-lowering-therapy-for-hypertriglyceridemia-induced-acute-pancreatitis-100622807","NCT07388420","Adding Evolocumab to Conventional Lipid-lowering Therapy for Hypertriglyceridemia Induced Acute Pancreatitis","Adding Evolocumab to Conventional Lipid-lowering Therapy for Hypertriglyceridemia Induced Acute Pancreatitis: A Pilot Randomised Controlled Trial","Inclusion Criteria:\n\n* Age 18\\~75 years\n* Patients with HTG-AP\n* Mixed hyperlipidemia\n* Sign the informed consent form\n\nExclusion Criteria:\n\n* Patients who have received lipid-lowering drugs or blood purification treatment\n* Patients who have used evolocumab within one month before admission\n* Patients who are accompanied by diseases that can seriously affect the survival\n* Patients who have participated in the clinical research of other drugs within one month\n* Patients who are pregnant or breastfeeding\n* Patients with allergic asthma, allergic urticaria, eczema, and those who have a clear history of multiple drug and food allergies\n* Other circumstances that researchers consider not suitable for participation in this study","75 Years",{"count":325,"type":22},40,[52],"The severity of hypertriglyceridemia induced acute pancreatitis (HTG-AP) is closely related to the serum triglyceride (TG) levels. The higher the TG levels, the greater the risk of developing severe acute pancreatitis (SAP). Previous expert consensus has pointed out that the key to treating HTG-AP is to rapidly lower serum TG levels to below 5.65 mmol\u002FL. Evolocumab is a proprotein convertase subtilisin\u002Fkexin type 9 (PCSK9) inhibitor, which is often used to treat familial hypercholesterolemia, mixed dyslipidemia and atherosclerotic cardiovascular disease. At the same time, evolocumab also has the effect of reducing TG and may provide a feasible option for the management of HTG-AP. However, its efficacy and safety in reducing TG in patients with HTG-AP remain controversial. This study is a multicenter randomized controlled trial to evaluate the efficacy and safety of adding evolocumab to conventional lipid-lowering therapy in patients with HTG-AP.",[329],"Hypertriglyceridemia Induced Acute Pancreatitis",[329,331,332],"Evolocumab","Conventional lipid-lowering therapy","2026-01-30",{"date":335,"type":33},"2026-02-05",{"date":337,"type":33},"2026-01-02",{"date":339,"type":22},"2026-12-31",{"name":39,"class":40},{"id":342,"slug":343,"hasResults":12,"nctId":344,"briefTitle":345,"officialTitle":346,"acronym":4,"eligibilityCriteria":347,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":348,"targetDuration":4,"studyType":23,"phases":350,"briefSummary":351,"conditions":352,"keywords":4,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":353,"lastUpdatePostDateStruct":354,"startDateStruct":356,"completionDateStruct":358,"leadSponsor":359,"locationsCount":41},"100614712","phase-2-tenecteplase-plus-urinary-kallidinogenase-for-acute-ischemic-stroke-tukis-100614712","NCT07283159","Tenecteplase Plus Urinary Kallidinogenase for Acute Ischemic Stroke (TUKIS)","Tenecteplase Plus Urinary Kallidinogenase for Acute Ischemic Stroke (TUKIS): a Prospective, Randomized, Double Blinded and Multi-center Study","Inclusion Criteria:\n\n* Age ≥ 18 year;\n* Acute ischemic stroke confirmed by neuroimaging;\n* The time from last known well to treatment is within 4.5 hours;\n* NIHSS ≥ 6 at randomization;\n* Received intravenous tenecteplase (0.25mg\u002Fkg);\n* First stroke onset or past stroke without obvious neurological deficit (mRS≤1);\n* Signed informed consent.\n\nExclusion Criteria:\n\n* Planed for endovascular treatment;\n* Use of Edaravone Injection, Edaravone Dexborneol Injection, Butylphthalide Injection or Capsules after the onset of the current episode；\n* Prior use of ACE inhibitors within a period less than 5 half-lives before the intended administration of Urinary Kallidinogenase for Injection；\n* Pregnancy；\n* Allergy to the investigational drug(s)；\n* Comorbidity with other serious diseases;\n* Participating in other clinical trials within 3 months;\n* Patients not suitable for the study considered by researcher.",{"count":349,"type":22},200,[25],"Human urinary kallidinogenase (HUK) is a tissue kallikrein extracted from human urine. Under certain conditions, tissue kallikrein can convert kininogen into kallidin and kinins, thereby promoting vascular endothelial function, and exerting anti-inflammatory and antioxidant effects. Preclinical and clinical studies have demonstrated that HUK can salvage the ischemic penumbra and significantly promote the establishment of collateral circulation. Existing research suggests that the combination of HUK with intravenous alteplase significantly improves neurological function in patients with acute ischemic stroke (AIS) without increasing the risk of hemorrhage. However, whether its combination with tenecteplase can further enhance neurological recovery in patients remains unreported. Based on the above discussion, this study aims to investigate the efficacy and safety of combining tenecteplase with HUK in the treatment of AIS.",[85],"2026-01-22",{"date":355,"type":33},"2026-01-23",{"date":357,"type":33},"2026-01-20",{"date":37,"type":22},{"name":39,"class":40},{"id":361,"slug":362,"hasResults":12,"nctId":363,"briefTitle":364,"officialTitle":365,"acronym":4,"eligibilityCriteria":366,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":367,"targetDuration":4,"studyType":210,"phases":4,"briefSummary":369,"conditions":370,"keywords":4,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":371,"lastUpdatePostDateStruct":372,"startDateStruct":374,"completionDateStruct":376,"leadSponsor":377,"locationsCount":41},"100619437","effects-of-short-term-intensive-statin-therapy-on-lipid-levels-100619437","NCT07344610","Effects of Short-term Intensive Statin Therapy on Lipid Levels","Effects of Short-term Intensive Statin Therapy on Lipid Levels in Patients With Ischemic Stroke or Large Artery Atherosclerosis: A Prospective Observational Study","Inclusion Criteria:\n\n* Age ≥ 18 years;\n* Diagnosis of ischemic stroke (within 14 days of onset) confirmed by cranial CT\u002FMRI; or imaging-confirmed intracranial\u002Fextracranial atherosclerotic stenosis (stenosis rate ≥ 50%);\n* Intensive statin therapy (e.g., atorvastatin 40-80 mg\u002Fday or rosuvastatin 20 mg\u002Fday) initiated within 24 hours of admission, with a planned continuous application for at least one week;\n* Signed informed consent form.\n\nExclusion Criteria:\n\n* Use of statin therapy within 1 week prior to admission;\n* Receiving other lipid-lowering treatments;\n* Presence of other serious comorbidities (e.g., malignant tumors, end-stage heart failure) with an expected survival of \\\u003C1 year;\n* Pregnant or lactating women;\n* Participation in other drug clinical trials within 3 months;\n* Other conditions deemed unsuitable by the investigator.",{"count":368,"type":22},800,"Acute cerebral infarction (ACI), often linked to arterial stenosis, is a major cause of death and disability. Statins are cornerstone therapies for secondary prevention, effectively lowering LDL-C and stabilizing plaques. However, patient response to intensive statin therapy varies significantly. This prospective study aims to analyze the short-term lipid-lowering effects and influencing factors of such therapy in ACI patients with stenosis, to guide personalized treatment and improve outcomes.",[85],"2026-01-07",{"date":373,"type":33},"2026-01-15",{"date":375,"type":33},"2026-01-08",{"date":118,"type":22},{"name":39,"class":40},{"id":379,"slug":380,"hasResults":12,"nctId":381,"briefTitle":382,"officialTitle":383,"acronym":4,"eligibilityCriteria":384,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":385,"targetDuration":4,"studyType":23,"phases":386,"briefSummary":387,"conditions":388,"keywords":390,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":396,"lastUpdatePostDateStruct":397,"startDateStruct":399,"completionDateStruct":401,"leadSponsor":403,"locationsCount":41},"100586998","glucocorticoids-for-acute-drug-induced-liver-injury-with-hyperbilirubinemia-100586998","NCT06922669","Glucocorticoids for Acute Drug Induced Liver Injury With Hyperbilirubinemia","Efficacy and Safety of Glucocorticoids for Acute Drug Induced Liver Injury With Hyperbilirubinemia: A Multicenter Randomized Controlled Trial","Inclusion Criteria:\n\n* A definite diagnosis of acute DILI;\n* 5×ULN ≤ TBIL level at baseline ≤ 20×ULN;\n* Age 18-80 years old;\n* Sign the informed consent form.\n\nExclusion Criteria:\n\n* Other causes of liver injury, including viral hepatitis, cytomegalovirus infection, Epstein-Barr virus infection, Herpes virus infection, autoimmune liver disease, alcoholic liver disease, hypoxic\u002Fischemic liver disease, Budd-Chiari syndrome, biliary tract disease, Wilson's disease, hemochromatosis, and α1-antitrypsin deficiency;\n* Immune checkpoint inhibitors or gynura segetum induced DILI;\n* Absolute contraindications to glucocorticoids, such as systemic mold infections or allergies;\n* A history of glucocorticoid therapy within 3 months before enrollment;\n* A history of diseases requiring glucocorticoid maintenance therapy, such as rheumatoid arthritis, systemic lupus erythematosus, systemic dermatomyositis, etc;\n* A history of liver transplantation;\n* Received artificial liver therapy before enrollment;\n* Malignant tumor of the liver, bile duct, pancreas or liver metastasis\n* Acute liver failure;\n* Renal dysfunction, creatinine Cr≥133μmol\u002FL;\n* Neutrophil count \\\u003C1,000,000,000\u002FL;\n* Active tuberculosis;\n* Severe cardiopulmonary diseases;\n* Recent surgery or trauma;\n* Mental illness;\n* Pregnancy or lactation;\n* Participated in other clinical studies within 3 months before enrollment;\n* Other conditions judged by the clinician to be inappropriate for study participation.",{"count":285,"type":22},[52],"Drug-induced liver injury (DILI) can lead to potentially fatal complications, such as acute liver failure and even death. In clinical practice, glucocorticoids have been considered in some cases of DILI, especially patients with hyperbilirubinemia. However, the available evidence remains controversial and its quality is also very limited. Herein, a multicenter randomized controlled trial (RCT) has been designed to explore the efficacy and safety of glucocorticoids in patients with acute DILI and hyperbilirubinemia.",[389],"Drug Induced Liver Injury",[391,392,393,394,395],"Drug induced liver injury","liver failure","glucocorticoids","clinical trial","Hyperbilirubinemia","2025-12-17",{"date":398,"type":33},"2025-12-18",{"date":400,"type":33},"2025-06-24",{"date":402,"type":22},"2027-09-30",{"name":39,"class":40},{"id":405,"slug":406,"hasResults":12,"nctId":407,"briefTitle":408,"officialTitle":409,"acronym":4,"eligibilityCriteria":410,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":411,"targetDuration":4,"studyType":23,"phases":413,"briefSummary":414,"conditions":415,"keywords":417,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":396,"lastUpdatePostDateStruct":419,"startDateStruct":421,"completionDateStruct":423,"leadSponsor":424,"locationsCount":41},"100547628","efficacy-and-safety-of-local-glucocorticoids-for-the-treatment-of-acute-radiation-induced-intestinal-injury-100547628","NCT06410443","Efficacy and Safety of Local Glucocorticoids for the Treatment of Acute Radiation-Induced Intestinal Injury","Efficacy and Safety of Local Glucocorticoids for the Treatment of Acute Radiation-Induced Intestinal Injury: A Randomized Controlled Trial","Inclusion Criteria:\n\n1. Grade II-III acute radiation-induced rectosigmoid injury\n2. Signed informed consents\n3. Age ≥18 years\n4. Rstimated survival time \\>1 year\n\nExclusion Criteria:\n\n1. Absolute contraindications to glucocorticoids\n2. A history of glucocorticoids treatment within 3 months\n3. Inflammatory bowel disease or infectious intestinal disease\n4. Recurrence of malignant tumor\n5. Colorectal cancer or metastasis\n6. Severe heart or lung diseases\n7. Recent history of surgery or trauma\n8. Poorly controlled hyperglycemia and hypertension\n9. Active tuberculosis\n10. Ssevere gastrointestinal ulcers\n11. Glaucoma\n12. Sychiatric diseases\n13. Pregnant or lactating",{"count":412,"type":22},60,[52],"Due to the increasing number and prolonged survival of malignant tumor patients treated with radiotherapy, the complication, such as acute radiation-induced intestinal injury, has become increasingly significant. Glucocorticoids may play a therapeutic role by regulating the inflammatory response in patients with acute radiation-induced intestinal injury. However, the conclusions of related studies were controversial.",[416],"Radiation-Induced Intestinal Injury",[416,418],"glucocorticoid",{"date":420,"type":33},"2025-12-24",{"date":422,"type":33},"2024-08-01",{"date":339,"type":22},{"name":39,"class":40},{"id":426,"slug":427,"hasResults":12,"nctId":428,"briefTitle":429,"officialTitle":430,"acronym":431,"eligibilityCriteria":432,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":433,"targetDuration":4,"studyType":23,"phases":435,"briefSummary":437,"conditions":438,"keywords":4,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":439,"lastUpdatePostDateStruct":440,"startDateStruct":442,"completionDateStruct":444,"leadSponsor":445,"locationsCount":41},"100603328","phase-3-improving-neuroprotective-strategy-for-ischemic-stroke-before-endovascular-thrombectomy-by-intravenous-tirofiban-100603328","NCT07135089","Improving Neuroprotective Strategy for Ischemic Stroke Before Endovascular Thrombectomy by Intravenous Tirofiban","Improving Neuroprotective Strategy for Ischemic Stroke Before Endovascular Thrombectomy by Intravenous Tirofiban (INSIST-IT2): a Prospective, Randomized, Double Blinded, Multi-center Study","INSIST-IT2","Inclusion Criteria:\n\n* Age ≥ 18 years;\n* Anterior circulation large vessel occlusion (the internal carotid artery or the first or second segment of the middle cerebral artery) confirmed by computed tomography angiography (CTA) or magnetic resonance angiography (MRA);\n* Eligible for endovascular treatment within 12 hours of symptom onset;\n* Based on the patient's medical history, clinical presentation, and imaging findings, large artery atherosclerosis is highly suspected as the underlying etiology;\n* Baseline National Institute of Health Stroke Scale (NIHSS) ≥ 6;\n* Baseline ASPECTS ≥ 6 on CT;\n* A pre-stroke modified Rankin Scale (mRS) score of ≤2;\n* Signed informed consent by patient or their legally authorized representative.\n\nExclusion Criteria:\n\n* History of atrial fibrillation or atrial flutter, or 12-lead Electrocardiogram before randomization and after admission showing atrial flutter or atrial fibrillation;\n* Hemorrhagic stroke: cerebral hemorrhage, subarachnoid hemorrhage, or a history of bleeding within one month;\n* Intracranial aneurysms or malformations, tortuous arteries that hinder thrombectomy, and space-occupying effect brain tumors;\n* The following drugs are taken within one week: dual antiplatelet drugs, direct oral anticoagulants (DOACs), warfarin and other drugs that increase the risk of bleeding;\n* Severe uncontrolled hypertension (systolic blood pressure over 200mmHg or diastolic blood pressure over 110 mmHg);\n* Deficiency of anticoagulant factors or international normalized ratio (INR) \\> 1.7, platelet count \\\u003C 90×10⁹\u002FL;;\n* Severe renal insufficiency and advanced disease with an expected life expectancy of less than 6 months;\n* Pregnancy or lactation;\n* Allergy to drugs or contrast agents;\n* Participating in other clinical trials;\n* Other conditions that the researcher deems unsuitable for participation in this study.",{"count":434,"type":22},870,[436],"PHASE3","It remains uncertain whether intravenous tirofiban administered before endovascular thrombectomy could improve disability severity for patients with LVO due to intracranial atherosclerosis.The current study aimed to assess the efficacy and safety of administering intravenous tirofiban before endovascular thrombectomy for improving clinical outcomes in patients with anterior circulation LVO due to intracranial atherosclerosis.",[156],"2025-12-02",{"date":441,"type":33},"2025-12-09",{"date":443,"type":33},"2025-11-13",{"date":37,"type":22},{"name":39,"class":40},{"id":447,"slug":448,"hasResults":12,"nctId":449,"briefTitle":450,"officialTitle":451,"acronym":4,"eligibilityCriteria":452,"healthyVolunteers":12,"sex":17,"minAge":150,"maxAge":4,"enrollmentInfo":453,"targetDuration":455,"studyType":210,"phases":4,"briefSummary":456,"conditions":457,"keywords":4,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":459,"lastUpdatePostDateStruct":460,"startDateStruct":462,"completionDateStruct":464,"leadSponsor":465,"locationsCount":41},"100613768","the-long-term-effect-of-remote-ischemic-conditioning-on-main-organs-in-asvcd-patients-with-very-high-risks-100613768","NCT07270887","The Long-term Effect of Remote Ischemic Conditioning on Main Organs in ASVCD Patients With Very High Risks","The Long-term Effect of Remote Ischemic Conditioning on Main Organs in ASVCD Patients With Very High Risks (RICMO-ASCVD): a Prospective, Blinded Endpoint, Multi-center, Cohort Study","Inclusion Criteria:\n\n* Age over 40 years\n* Two or more prior major ASCVD events; OR one documented major ASCVD event with two or more of the following risk factors\n* signed informed consent\n\nNote： Definition of Major ASCVD Events:\n\nA. Acute coronary syndrome within the past year. B. History of myocardial infarction (not part of a new acute coronary syndrome episode).\n\nC. Ischemic stroke or history of ischemic stroke. D. Symptomatic peripheral artery disease, defined as intermittent claudication with an ankle-brachial index (ABI) \\\u003C 0.85, or prior limb revascularization or amputation.\n\nRisk factors:\n\n1. Age ≥65 y\n2. Heterozygous familial hypercholesterolemia\n3. History of prior coronary artery bypass surgery or percutaneous coronary intervention outside of the major\n4. ASCVD event(s)\n5. Diabetes mellitus\n6. Hypertension\n7. CKD (eGFR 15-59 mL\u002Fmin\u002F1.73 m2)\n8. Current smoking\n9. Persistently elevated LDL-C (LDL-C ≥100 mg\u002FdL \\[≥2.6 mmol\u002FL\\]) despite maximally tolerated statin therapy and ezetimibe\n10. History of congestive HF\n\nExclusion Criteria:\n\n* Presence of severe neurological deficit (mRS score ≥ 3)\n* Uncontrolled severe hypertension (systolic blood pressure \\> 180 mmHg or diastolic blood pressure \\> 110 mmHg despite medication)\n* Subclavian artery stenosis ≥ 50% or presence of subclavian steal syndrome\n* Severe hematological disorders or significant coagulation abnormalities\n* Contraindications to remote ischemic conditioning, such as severe soft tissue injury, fracture, or vascular injury in the upper limbs, or peripheral vascular disease in the distal upper limbs\n* Severe comorbid conditions with a life expectancy of less than 1 year\n* Participation in another clinical trial within the past 3 months or ongoing participation\n* Any other circumstances deemed by the investigator as unsuitable for participation in this clinical study.",{"count":454,"type":22},2800,"1 Year","Atherosclerotic cardiovascular disease (ASCVD) is a group of disorders sharing atherosclerosis as a common pathological basis, primarily affecting the heart, brain, kidneys, and other peripheral arteries, leading to clinical syndromes characterized mainly by arterial ischemia. It has become the group of diseases with the highest morbidity and mortality rates worldwide. Patients with very high-risk ASCVD face an even greater risk of recurrence. Previous studies have discovered that remote ischemic conditioning (RIC) has protective effects on major organs such as the heart, brain, and kidneys. Given the cardiorenal and cerebrovascular protective effects of RIC, the invesitgators believe that long-term remote ischemic conditioning is a promising approach to preventing the recurrence of ASCVD events. Based on this hypothesis, the investigators have designed a prospective, multicenter cohort study with blinded outcome assessment to investigate the protective effects of long-term remote ischemic conditioning in very high-risk ASCVD populations.",[458],"ASCVD","2025-11-26",{"date":461,"type":33},"2025-12-08",{"date":463,"type":33},"2025-11-19",{"date":37,"type":22},{"name":39,"class":40},{"id":467,"slug":468,"hasResults":12,"nctId":469,"briefTitle":470,"officialTitle":471,"acronym":4,"eligibilityCriteria":472,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":473,"enrollmentInfo":474,"targetDuration":4,"studyType":23,"phases":476,"briefSummary":477,"conditions":478,"keywords":480,"overallStatus":63,"whyStopped":4,"lastUpdateSubmitDate":463,"lastUpdatePostDateStruct":486,"startDateStruct":487,"completionDateStruct":489,"leadSponsor":491,"locationsCount":41},"100612347","terlipressin-vs-somatostatin-in-cirrhotic-patients-with-acute-gastrointestinal-bleeding-and-acute-kidney-injury-100612347","NCT07252401","Terlipressin vs. Somatostatin in Cirrhotic Patients With Acute Gastrointestinal Bleeding and Acute Kidney Injury","Terlipressin vs. Somatostatin in Cirrhotic Patients With Acute Gastrointestinal Bleeding and Acute Kidney Injury: A Multicenter Randomized Controlled Trial","Inclusion Criteria:\n\n* patients have a definite diagnosis of live cirrhosis and AKI;\n* patients present with AGIB at admission;\n* patients' age 18-70 years old;\n* patients or relatives can sign the informed consent form.\n\nExclusion Criteria:\n\n* patients have hepatorenal syndrome- acute renal injury (HRS-AKI);\n* patients have structural kidney injury;\n* patients have chronic kidney disease;\n* patients received terlipressin or somatostatin therapy within 48 hours before enrollment;\n* patients received kidney replacement therapy before enrollment;\n* patients have a history of liver transplantation or TIPS;\n* patients have acute liver failure or acute-on-chronic liver failure;\n* patients have hepatic or renal malignant tumor;\n* patients have severe diseases of the heart, lungs, and brain;\n* patients have contraindications for experimental drugs;\n* patients are in pregnancy or lactation;\n* patients participated in other clinical studies within 3 months before enrollment;\n* patients have other conditions that investigators deem unsuitable for enrollment in the study.","70 Years",{"count":475,"type":22},64,[52],"Acute gastrointestinal bleeding (AGIB) is a common complication in the decompensated stage of liver cirrhosis, of which approximately 70% is acute variceal bleeding (AVB) caused by portal hypertension. Existing evidence suggests that both terlipressin and somatostatin can be used to control AVB in cirrhotic patients, but terlipressin may be the first-line treatment for cirrhotic patients with AGIB complicated by acute kidney injury (AKI). Herein, a multicenter randomized controlled trial (RCT) has been designed to compare the efficacy of terlipressin and somatostatin in the treatment of cirrhotic patients with AGIB complicated by AKI.",[479],"Liver Cirrhosis",[481,482,483,484,485],"acute gastrointestinal bleeding","acute kidney injury","terlipressin","somatostatin","liver cirrhosis",{"date":459,"type":33},{"date":488,"type":22},"2025-12-25",{"date":490,"type":22},"2028-03-31",{"name":39,"class":40},{"id":493,"slug":494,"hasResults":12,"nctId":495,"briefTitle":496,"officialTitle":497,"acronym":4,"eligibilityCriteria":498,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":499,"targetDuration":4,"studyType":23,"phases":501,"briefSummary":502,"conditions":503,"keywords":4,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":504,"lastUpdatePostDateStruct":505,"startDateStruct":507,"completionDateStruct":509,"leadSponsor":511,"locationsCount":41},"100606225","head-down-position-before-endovascular-treatment-for-large-vessel-occlusion-hopes5-100606225","NCT07172789","Head dOwn Position Before Endovascular Treatment for Large veSsel Occlusion (HOPES5)","Head dOwn Position Before Endovascular Treatment for Large veSsel Occlusion (HOPES5): a Prospective, Randomized, Open Label, Blinded-end Point, Multi-center Study","Inclusion Criteria:\n\n* Age ≥ 18 years;\n* Patients with acute large vessel occlusion scheduled for endovascular thrombectomy within 24 hours of symptom onset;\n* Baseline National Institute of Health Stroke Scale (NIHSS) ≥ 6;\n* Expected waiting time from randomization to femoral artery puncture is more than 30 minutes;\n* ASPECTS\u002Fpc-ASPECTS score ≥ 6 on baseline non-contrast CT or DWI;\n* Modified Rankin Scale score before stroke onset ≤ 1;\n* Signed informed consent by patient or their legally authorized representative.\n\nExclusion Criteria:\n\n* Hemorrhagic stroke: cerebral hemorrhage, subarachnoid hemorrhage;\n* Severe hepatic or renal dysfunction, increase in ALT or AST (more than 2 times of upper limit of normal value), increase in serum creatinine (more than 1.5 times of upper limit of normal value) or requiring dialysis;\n* Severe hypertension before randomization (systolic blood pressure \\>185 mmHg or diastolic blood pressure \\>110 mmHg);\n* Cardiac insufficiency (NYHA Class ≥II);\n* Pregnancy, plan to get pregnant or during lactation;\n* Patients at significant risk of aspiration (e.g., obvious nausea and vomiting);\n* The estimated life expectancy is less than 6 months due to other serious diseases;\n* Other conditions unsuitable for this clinical study assessed by researcher.",{"count":500,"type":22},210,[52],"Recent studies suggest that head-down positioning (HDP) intervention may improve outcomes in ischemic stroke. In the era of reperfusion therapy, a key protective strategy is to administer neuroprotective interventions before recanalization to reduce the loss of the ischemic penumbra, thereby salvaging more penumbral tissue after revascularization and ultimately improving clinical outcomes. Based on this concept, and considering the neuroprotective effects of HDP, the investigators hypothesize that HDP intervention prior to endovascular therapy (EVT) in patients with large vessel occlusion could improve clinical outcomes. This hypothesis is further supported by a recent clinical study (NCT03728738), which demonstrated that compared to a sitting up position (30°), a flat supine position (0°) before EVT significantly reduced the incidence of neurological deterioration prior to the procedure. Building on the above rationale, this trial aims to investigate the efficacy and safety of HDP intervention prior to EVT in patients with large vessel occlusion.",[85],"2025-09-08",{"date":506,"type":33},"2025-09-15",{"date":508,"type":33},"2025-09-02",{"date":510,"type":22},"2026-09-30",{"name":39,"class":40},{"id":513,"slug":514,"hasResults":12,"nctId":515,"briefTitle":516,"officialTitle":517,"acronym":4,"eligibilityCriteria":518,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":519,"targetDuration":4,"studyType":23,"phases":521,"briefSummary":522,"conditions":523,"keywords":525,"overallStatus":63,"whyStopped":4,"lastUpdateSubmitDate":529,"lastUpdatePostDateStruct":530,"startDateStruct":532,"completionDateStruct":534,"leadSponsor":536,"locationsCount":41},"100591751","human-umbilical-cord-mesenchymal-stem-cells-via-different-transplantation-routes-in-esld-100591751","NCT06984497","Human Umbilical Cord-mesenchymal Stem Cells Via Different Transplantation Routes in ESLD","Efficacy and Safety of Different Transplantation Routes of Human Umbilical Cord-mesenchymal Stem Cells in Patients With End-stage Liver Disease","Inclusion Criteria:\n\n1. 18-80 years old\n\n   \\-\n2. End-stage liver disease\n\n   \\-\n3. Signed informed consent\n\nExclusion Criteria:\n\n1. Tumours of the liver or other organs\n\n   \\-\n2. Liver transplantation recipients\n\n   \\-\n3. Acute myocardial infarction, acute heart failure, type I and type II respiratory failure, pulmonary embolism, acute cerebral infarction, acute cerebral haemorrhage and other serious cardiopulmonary diseases\n\n   \\-\n4. Other diseases that may seriously affect the survival\n\n   \\-\n5. Human immunodeficiency syndrome\n\n   \\-\n6. Interferon or glucocorticoid therapy within 1 year\n\n   \\-\n7. Treated for mental illness\n\n   \\-\n8. Participation in other clinical trials within 30 days\n\n   \\-\n9. Pregnant or breastfeeding subjects\n\n   \\-\n10. Allergic asthma, allergic urticaria, eczema, or a history of multiple drug and food allergies\n\n    \\-\n11. Other circumstances that are unsuitable for participation in this study",{"count":520,"type":22},32,[52],"Stem cells are non-terminal cells that can self renew and replicate through symmetric or asymmetric division, with the potential to differentiate into different types of cells and tissues. Multiple studies have shown that human umbilical cord mesenchymal stem cell has good safety and effectiveness in improving acute or chronic liver injury.\n\nStem cell therapy for end-stage liver disease (ESLD) can be administered through various routes, among which hepatic artery and peripheral vein infusions are the most commonly used in clinical practice. The efficacy of hepatic artery infusion appears to be greater than that of peripheral vein infusion.",[524],"End-Stage Liver Diseases",[57,526,527,528],"end-stage liver diseases","umbilical cord-mesenchymal stem cells","randomized controlled trial","2025-08-22",{"date":531,"type":33},"2025-08-24",{"date":533,"type":22},"2025-09",{"date":535,"type":22},"2027-12",{"name":39,"class":40},{"id":538,"slug":539,"hasResults":12,"nctId":540,"briefTitle":541,"officialTitle":542,"acronym":4,"eligibilityCriteria":543,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":544,"targetDuration":545,"studyType":210,"phases":4,"briefSummary":546,"conditions":547,"keywords":4,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":548,"lastUpdatePostDateStruct":549,"startDateStruct":551,"completionDateStruct":553,"leadSponsor":554,"locationsCount":41},"100545536","change-in-serum-biomarkers-after-endovascular-treatment-for-acute-anterior-circulation-large-vessel-occlusion-100545536","NCT06383182","Change in Serum Biomarkers After Endovascular Treatment for Acute Anterior Circulation Large Vessel Occlusion","Change in Serum Biomarkers After Endovascular Treatment for Acute Anterior Circulation Large Vessel Occlusion: a Prospective, Registry Study","Inclusion Criteria:\n\n1. Age: 18-80 years;\n2. Patients with acute anterior circulation large vessel occlusion within 24 hours of onset who will receive endovascular treatment;\n3. Pre-stroke mRS: 0-1;\n4. Baseline NIHSS: ≥6;\n5. Signed informed consent.\n\nExclusion Criteria:\n\n1. The presence of contraindications to internal jugular vein cannulation;\n2. Receiving intravenous thrombolysis;\n3. Haemorrhagic stroke (cerebral haemorrhage or subarachnoid haemorrhage);\n4. Coagulation disorders, systemic bleeding tendency, thrombocytopenia (\\\u003C100×109\u002FL);\n5. Severe cardiac, hepatic or renal insufficiency (ALT or AST elevated more than 2 times the upper limit of normal value, or serum creatinine elevated more than 1.5 times the upper limit of normal value or in need of dialysis) or other serious medical diseases;\n6. Severe uncontrolled hypertension (systolic blood pressure greater than 200 mmHg or diastolic blood pressure greater than 110 mmHg);\n7. Pregnant or lactating women;\n8. Other conditions who are not suitable for this trial by investigator.",{"count":349,"type":22},"90 Days","Acute ischaemic stroke (AIS) results in high rates of neurological morbidity and mortality, especially in patients with large vessel occlusion (LVO). Endovascular therapy (EVT) has been approved as the most effective treatment for patients with LVO , but about half patients undergoing EVT did not achieve good outcome. The mechanisms of poor prognosis are complex. How to accurately identify serological biomarkers related to patients' clinical prognosis is an important research topic nowadays.",[85],"2025-08-20",{"date":550,"type":33},"2025-08-21",{"date":552,"type":33},"2024-07-02",{"date":118,"type":22},{"name":39,"class":40},""]